Amneal Pharmaceuticals (AMRX) Stock Statistics & Valuation Metrics

Amneal Pharmaceuticals has a market cap or net worth of $3.40B. The enterprise value is $5.17B.

Amneal Pharmaceuticals has 314,079,300 shares outstanding. The number of shares has decreased by -2.65% in one year.

Amneal Pharmaceuticals’s return on equity (ROE) is 1.07 and return on invested capital (ROIC) is 12.35%.

The current PE Ratio of Amneal Pharmaceuticals is 751.4. Amneal Pharmaceuticals’s PEG ratio is 1.00.

In the last 12 months, Amneal Pharmaceuticals had revenue of 2.79B and earned -116.89M in profits. Earnings per share was -0.38.

In the last 12 months, operating cash flow was 209.31M and capital expenditures -67.89M, giving a free cash flow of 141.42M billion.

Amneal Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Amneal Pharmaceuticals upcoming earnings date is Mar 4, 2026, Before Open (Confirmed).

Amneal Pharmaceuticals as a current ratio of 1.41, with Debt / Equity ratio of 14.54%

In the past 12 months, Amneal Pharmaceuticals has paid 18.86M in taxes.

Amneal Pharmaceuticals EV to EBITDA ratio is 11.21, with an EV/FCF ratio of 20.27.

Amneal Pharmaceuticals has $201.25M in cash and marketable securities with $119.22M in debt, giving a net cash position of $82.03M billion.

Gross margin is 36.76%, with operating margin of 8.92%, and net profit margin of -4.18%.

The average price target for Amneal Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is Moderate Buy